drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous gene-modified T cells expressing a chimeric antigen receptor targeting cadherin-17 (CDH17), infused intravenously to mediate targeted cytotoxicity against CDH17-positive tumors after lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor targeting cadherin-17 (CDH17). Upon binding CDH17 on tumor cells, CAR signaling activates T-cell effector functions, leading to proliferation, cytokine release, and targeted cytotoxic killing of CDH17-positive tumors following lymphodepleting conditioning.
drug_name
Anti-CDH17 CAR-T cells
nct_id_drug_ref
NCT06501183